HuGE Literature Finder
Records
1
-
1
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology (Baltimore, Md.) 2013 Jan . Wedemeyer H, Jensen D, Herring R, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Lou Munson M, Chen YC, Najera I, Thommes J |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 27, 2022
- Content source: